J&J hopes to boost vax business with Crucell buy

The world's largest diversified healthcare group Johnson & Johnson said Wednesday it will buy Dutch biotechnology firm Crucell for €1.75 billion ($2.4 billion)--a move that will help it boost its vaccine business. J&J said Crucell's board has agreed to the takeover offer and has recommended the bid to its shareholders. Article